This observation, in addition to our previous report that the basophil activation test predicted hypersensitivity to the first anti-tumor IgE therapeutic candidate MOv18 IgE, suggests that basophils may serve as predictive or monitoring tools for the development of hypersensitivity to therapeutic agents in oncology (AllergoOncology). This evidence concerns the gene IGHE and neoplasm.